Soares_et_al-2018-British_Journal_of_Dermatology.pdf (120.57 kB)
Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs
journal contribution
posted on 2023-06-09, 12:43 authored by P Soares, Katy FidlerKaty Fidler, J Felton, R Tavendale, A Hövels, Stephen BremnerStephen Bremner, C N A Palmer, Somnath MukhopadhyaySomnath MukhopadhyayBackground Eczema and asthma are chronic diseases with onset usually before the age of 5 years. More than 50% of individuals with eczema will develop asthma and/or other allergic diseases. Several loss-of-function mutations in filaggrin (FLG) have been identified in patients with eczema. However, the association of FLG with healthcare use is unknown. Objectives To determine whether FLG mutations are associated with increased prescribing for eczema and asthma and whether increased prescribing is associated with increased healthcare costs. Methods A secondary analysis of BREATHE, a cross-sectional study of gene–environment associations with asthma severity, was undertaken. BREATHE data was collected for 1100 participants with asthma, in Tayside and Fife, Scotland during the period 2003–2005. Through collaboration with the Health Informatics Centre in Dundee, BREATHE was linked to accident and emergency, community prescribing and Scottish morbidity records. The data linkage allowed longitudinal exploration of associations between genetic variation and prescribing. Results An association was found between FLG mutations and increased prescribing for mild and moderate eczema, asthma-reliever medicine and asthma exacerbations. A strong association was found between FLG mutations and prescribing of emollients [incidence rate ratio (IRR) 2·19, 95% confidence interval (CI) 1·36–3·52], treatment for severe eczema (IRR 2·18, 95% CI 1·22–3·91) and a combination of a long-acting ß2-agonist and corticosteroids (IRR 3·29, 95% CI 1·68–6·43). Conclusions The presence of FLG mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomized controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.
History
Publication status
- Published
File Version
- Published version
Journal
British Journal of DermatologyISSN
1365-2133Publisher
Blackwell PublishingExternal DOI
Issue
3Volume
179Page range
717-723Department affiliated with
- BSMS Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2018-04-05First Open Access (FOA) Date
2018-08-15First Compliant Deposit (FCD) Date
2018-04-04Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC